Full-Time

Supervisor

Investigator Payments

Confirmed live in the last 24 hours

Icon

Icon

10,001+ employees

Consulting and development services for pharmaceuticals

No salary listed

Mid, Senior

Chennai, Tamil Nadu, India

In Person

Category
Financial Planning and Analysis (FP&A)
Finance & Banking
Required Skills
Excel/Numbers/Sheets
Requirements
  • Minimum 3 years of experience of experience in a busy payment’s role
  • Excellent Excel knowledge
  • Candidate should be ambitious, able to multi-task & work well under pressure
  • Ability to work to tight deadlines
Responsibilities
  • To ensure performance of team is aligned with goals and objectives set.
  • To generate metrics in relation to same.
  • Reduction in Outstanding Payments (including invoices)
  • IPG Operational Metrics + Arrow + QC + Invoices
  • Mgmt. of metrics - according to the report assignment
  • Review of Dashboard for Outstanding payments
  • Clinical team meetings
  • Number of studies in each traffic light and % - green to be
  • List all reports and expected action
  • Minimize number of escalations and if arrive action asap
  • Review in terms of ageing and high value and volume
  • Be accountable for the quality of how each study assigned is set-up and maintained ensuring payments are correct and that all work carried out is in accordance with IPG processes and procedures and is audit ready.
  • Liaise with all other ICON departments such as Clinical, PTS, IT, Finance, legal and contracts to ensure payment queries are speedily resolved and that the necessary preventative measures are put in place to prevent recurrence of similar issues.

Icon provides consulting, development, and commercialization services to help clients in the pharmaceutical and medical device industries accelerate the creation of products that enhance health and well-being. Their services are designed to streamline the process of bringing drugs and devices to market by focusing on reducing time and costs while improving quality. With a presence in 53 countries, Icon has a global team of experts who specialize in various therapeutic areas, allowing them to offer tailored solutions to meet the specific needs of their clients. The company's goal is to support the development of life-saving products and improve the quality of life for patients.

Company Size

10,001+

Company Stage

IPO

Headquarters

Ireland

Founded

1990

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased use of AI accelerates clinical trial participant identification.
  • Partnership with Mural Health enhances trial participant and site experience.
  • Centre for Obesity expedites obesity-related clinical trials.

What critics are saying

  • Complexity of multi-indication trials may lead to inefficiencies.
  • Securities fraud lawsuit could cause financial and reputational damage.
  • Underutilization of biomarkers may hinder optimization of neurodegenerative trials.

What makes Icon unique

  • ICON offers a global network of offices in 53 countries.
  • The company focuses on reducing time to market, cost, and increasing quality.
  • ICON has extensive experience in a broad range of therapeutic areas.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

401(k) Retirement Plan

Mental Health Support

Life Insurance

Flexible Work Hours

Company News

ICON plc
Jun 24th, 2025
Expert insights for early-stage innovators from Bio€quity Europe 2025

At Bio€quity Europe 2025, the premier investor conference for European biopharma, ICON was proud to contribute to the conversation shaping the future of early-stage innovation.

BioSpace
May 7th, 2025
Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies

Alongside the whitepaper, ICON has launched their new Centre for Obesity that delivers expertise and market intelligence with a ready-to-deploy infrastructure of 100 sites and an in-development database of 10,000 pre-screened patients across the breadth of comorbidities related to obesity.

PharmiWeb
May 7th, 2025
Global Icon Survey Shows Need For More Efficient Obesity Clinical Trial Design To Realise Full Potential Of Next-Gen Multi-Indication Therapies

Dublin, Ireland – 7 May – ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic RD for therapies targeting obesity and its comorbidities. Multi-indication studies are clinical trials that test how a treatment works for more than one condition or disease. As researchers uncover the potential of particular drug classes across interconnected diseases, the commercial opportunities have increased the appetite for additional research that targets multiple indications. The findings indicate that most sponsors (83% of respondents) are pursuing multi-indication approaches in their obesity-related research. However, the survey results also suggest that sponsors may underestimate the complexity of these strategies - particularly when selecting inclusion criteria and endpoints - which can lead to inefficiencies in the clinical development process

Broad Street Hero
Apr 3rd, 2025
An old friend joins the Broadstreet team

After Oxford Outcomes was acquired by ICON Plc. she honed her expertise in real world evidence (RWE), spending a lot of her time on multi-national projects including prospective studies, retrospective database and chart reviews, and eliciting patient, caregiver and provider perspectives.

Rewbix
Mar 21st, 2025
Legal Turmoil for ICON Public Limited Company (ICLR): A Deep Dive into the Financial Impact of Securities Fraud Lawsuit

ICON Public Limited Company (ICLR), a leading healthcare and pharmaceutical services provider, has been hit by a securities fraud class-action lawsuit.